Eagle Pharmaceuticals
(NASDAQ:EGRX)
$5.24
0.23[4.59%]
At close: Mar 28
$5.24
0[0.00%]
After Hours: 4:03PM EDT
Consensus Rating1
Underweight
Highest Price Target1
$17.00
Lowest Price Target1
$17.00
Consensus Price Target1
$17.00

Eagle Pharmaceuticals Stock (NASDAQ:EGRX), Analyst Ratings, Price Targets, Predictions

Eagle Pharmaceuticals Inc has a consensus price target of $17, established from looking at the 1 latest analyst ratings. The last 1 analyst ratings were released from Piper Sandler on August 9, 2023. With an average price target of $17 between Piper Sandler, there's an implied 224.43% upside for Eagle Pharmaceuticals Inc from these 1 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Feb
0
0
0
0
0
Jan
0
0
0
0
0
Dec 23
0
0
0
0
0
Nov 23
0
0
0
0
0
Oct 23
0
0
0
0
0
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Eagle Pharmaceuticals

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
08/09/2023EGRXBuy Now
Eagle Pharmaceuticals
$5.24224.43%Piper Sandler
David Amsellem
$26 → $17DowngradeNeutral → UnderweightGet Alert

FAQ

Q

What is the target price for Eagle Pharmaceuticals (EGRX)?

A

The latest price target for Eagle Pharmaceuticals (NASDAQ: EGRX) was reported by Piper Sandler on August 9, 2023. The analyst firm set a price target for $17.00 expecting EGRX to rise to within 12 months (a possible 224.43% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Eagle Pharmaceuticals (EGRX)?

A

The latest analyst rating for Eagle Pharmaceuticals (NASDAQ: EGRX) was provided by Piper Sandler, and Eagle Pharmaceuticals downgraded their underweight rating.

Q

When was the last upgrade for Eagle Pharmaceuticals (EGRX)?

A

There is no last upgrade for Eagle Pharmaceuticals.

Q

When was the last downgrade for Eagle Pharmaceuticals (EGRX)?

A

The last downgrade for Eagle Pharmaceuticals Inc happened on August 9, 2023 when Piper Sandler changed their price target from $26 to $17 for Eagle Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Eagle Pharmaceuticals (EGRX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eagle Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eagle Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.

Q

Is the Analyst Rating Eagle Pharmaceuticals (EGRX) correct?

A

While ratings are subjective and will change, the latest Eagle Pharmaceuticals (EGRX) rating was a downgraded with a price target of $26.00 to $17.00. The current price Eagle Pharmaceuticals (EGRX) is trading at is $5.24, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch